Looking Ahead: Monitoring and Your Child's Future
At a Glance
Children with GHSR deficiency need individualized follow-up to track height, weight, growth speed, bone age, puberty, and, especially during growth hormone therapy, hormone and blood-sugar measures. Emotional well-being and support for treatment fatigue also matter.
Managing GHSR deficiency is a marathon, not a sprint. Because this condition is rare, your child’s long-term care will focus on maximizing their growth potential during childhood while keeping a close eye on their overall metabolic and emotional health [1].
The Surveillance Schedule: What to Expect
Ongoing care typically involves regular visits to a pediatric endocrinologist. While every child’s needs are different, a standard monitoring schedule often includes:
- Every 3–6 Months: Clinical visits to track serial height, weight, and growth velocity (the speed at which your child is growing) [2][3].
- Every 6–12 Months: Blood tests to monitor hormone levels, such as IGF-1 and thyroid function, especially if your child is on growth hormone therapy [4][3].
- Annually (or as needed): A bone age X-ray to see how much “growth room” remains in the bones [3].
These frequencies apply primarily to children receiving GH therapy. For untreated children, follow-up differs and routine serial IGF-1 or glucose testing is generally not required unless symptoms are present.
Puberty: The Final Growth Window
Puberty is a critical time for children with short stature. During this period, the body releases sex hormones (estrogen and testosterone) that cause a final “growth spurt” but also cause the growth plates in the bones to mature and eventually close [5][6].
In GHSR deficiency, puberty usually happens at a typical age [1]. Your doctor will monitor your child’s bone age closely during these years. If the bone age begins to advance too quickly, it can shorten the window of time available for growth hormone therapy to work [6]. The goal is to carefully time treatment to maximize your child’s final adult height before the growth plates close completely.
Long-Term Metabolic Health
Because the GHSR gene (the ghrelin receptor) is involved in how the body manages energy and sugar, doctors may monitor your child’s metabolic health as they grow [7].
- Glucose and Insulin: Growth hormone therapy can sometimes affect how the body processes sugar. Periodic blood tests for fasting glucose or HbA1c may be recommended to ensure your child’s metabolic system stays balanced [4][8].
- Energy Expenditure: While some animal studies show that a lack of ghrelin receptors can affect energy use, most children with this condition lead normal, healthy lives [9][10]. GHSR’s role in energy balance does not by itself establish a special human risk for diabetes or abnormal energy expenditure. Maintaining a healthy lifestyle with regular activity and good nutrition remains the best support for long-term health [11].
Expectations for Adulthood
The ultimate goal of early diagnosis and treatment is to help your child achieve a final height that is within or near the typical range for adults. Response varies, and treatment doesn’t guarantee a typical adult height.
Current research is encouraging. In small groups of children followed for several years, those who received treatment saw significant improvements in their height compared to where they started [1][12]. While long-term studies of adults with this specific genetic variant are still limited, no consistent multisystem pattern has been established so far, while acknowledging the uncertainty due to the lack of long-term adult data [1]. As your child finishes growing, pediatric endocrine follow-up will end, and you should discuss with your doctor whether genetic counseling remains useful.
Supporting the “Whole Child”
Living with a rare growth condition involves more than just physical monitoring. It can also carry a psychological weight for both the child and the parents.
- The Social Toll: Children who are significantly shorter than their peers may face social challenges, such as bullying or feeling “younger” than they are [13]. Research suggests that children who achieve a height closer to the typical range often report better social confidence [14].
- Treatment Burden: If your child is receiving daily or weekly injections, they may experience “treatment fatigue” [15]. It is important to acknowledge the effort they are making and to maintain an open dialogue about how they feel about their treatment [16].
- Caregiver Stress: Parents also carry a burden, from navigating insurance to managing the “diagnostic odyssey.” Seeking support through parent groups or counseling can help you stay resilient as you advocate for your child [17][18].
Focusing on your child’s strengths—their hobbies, friendships, and character—alongside their growth ensures they feel valued for who they are, not just how tall they are [19]. Support for school, bullying, body image, and treatment fatigue is vital whether or not the child reaches an average height.
Common questions in this guide
How often should my child with GHSR deficiency have growth checks?
Which blood tests may be used to monitor GHSR deficiency?
Why is bone age important during puberty?
Can growth hormone therapy ensure a typical adult height?
What support can help my child cope with short stature and treatment?
What happens when my child reaches final adult height?
Get notified when new evidence is published on Short stature due to GHSR deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (19)
- 1
Loss-of-Function GHSR Variants Are Associated With Short Stature and Low IGF-I.
Punt LD, Kooijman S, Mutsters NJM, et al.
The Journal of clinical endocrinology and metabolism 2025; (110(5)):e1303-e1314 doi:10.1210/clinem/dgaf010.
PMID: 39785833 - 2
Development of a Minimum Dataset for the Monitoring of Recombinant Human Growth Hormone Therapy in Children with Growth Hormone Deficiency: A GloBE-Reg Initiative.
Chen SC, Bryce J, Chen M, et al.
Hormone research in paediatrics 2024; (97(4)):365-373 doi:10.1159/000533763.
PMID: 37703843 - 3
Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center.
Al Shaikh A, Daftardar H, Alghamdi AA, et al.
Acta bio-medica : Atenei Parmensis 2020; (91(1)):29-40 doi:10.23750/abm.v91i1.9182.
PMID: 32191651 - 4
Delphi consensus on the diagnosis and treatment of patients with short stature in Spain: GROW-SENS study.
Corripio-Collado R, Fernández-Ramos C, González-Casado I, et al.
Journal of endocrinological investigation 2022; (45(4)):887-897 doi:10.1007/s40618-021-01696-0.
PMID: 34791604 - 5
Aromatase inhibitors for short stature in male children and adolescents.
McGrath N, O'Grady MJ
The Cochrane database of systematic reviews 2015; CD010888 doi:10.1002/14651858.CD010888.pub2.
PMID: 26447646 - 6
Efficacy and safety of recombinant human growth hormone in treating Chinese children with idiopathic short stature.
Ying YQ, Hou L, Liang Y, et al.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2018; (42-43()):80-85 doi:10.1016/j.ghir.2018.09.003.
PMID: 30343148 - 7
Ghrelin Receptor Mutations and Human Obesity.
Wang W, Tao YX
Progress in molecular biology and translational science 2016; (140()):131-50.
PMID: 27288828 - 8
Biological effects of recombinant human growth hormone therapy on metabolism in children with growth hormone deficiency: a review.
Dyrka K, Łachut K, Kolesińska Z, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2025; (38(8)):796-806 doi:10.1515/jpem-2025-0057.
PMID: 40320660 - 9
Genetic or pharmacological GHSR blockade has sexually dimorphic effects in rodents on a high-fat diet.
Lékó AH, Gregory-Flores A, Marchette RCN, et al.
Communications biology 2024; (7(1)):632 doi:10.1038/s42003-024-06303-5.
PMID: 38796563 - 10
Genetic or pharmacological GHSR blockade has sexually dimorphic effects in rodents on a high-fat diet.
Leggio L, Leko A, Gregory-Flores A, et al.
Research square 2023; doi:10.21203/rs.3.rs-3236045/v1.
PMID: 37886546 - 11
International Consensus Guideline on Small for Gestational Age: Etiology and Management From Infancy to Early Adulthood.
Hokken-Koelega ACS, van der Steen M, Boguszewski MCS, et al.
Endocrine reviews 2023; (44(3)):539-565 doi:10.1210/endrev/bnad002.
PMID: 36635911 - 12
Growth hormone treatment outcomes in children with genetic isolated growth hormone deficiency.
Aouchiche K, Castets S, Oliver Petit I, et al.
European journal of pediatrics 2025; (184(12)):812 doi:10.1007/s00431-025-06661-0.
PMID: 41326671 - 13
Growth hormone deficiency, bullying victimization, and associations with treatment status: a pediatric case-control study.
Kocabey Sutcu Z, Caliskan Y, Aytaç Kaplan EH
Journal of pediatric psychology 2026; (51(7)):612-620 doi:10.1093/jpepsy/jsag022.
PMID: 41843717 - 14
Associations between Psychological Problems and Quality of Life in Pediatric Short Stature from Patients' and Parents' Perspectives.
Quitmann JH, Bullinger M, Sommer R, et al.
PloS one 2016; (11(4)):e0153953 doi:10.1371/journal.pone.0153953.
PMID: 27097033 - 15
Adherence and quality of life in children receiving rhGH treatment.
Gonzalez-Briceño L, Viaud M, Polak M
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 2022; (28(8S1)):8S3-8S8 doi:10.1016/S0929-693X(22)00036-7.
PMID: 37870531 - 16
Treatment burden, adherence, and quality of life in children with daily GH treatment in France.
Coutant R, Tauber M, Demaret B, et al.
Endocrine connections 2023; (12(4)).
PMID: 36866786 - 17
Children's psychosocial functioning and parents' quality of life in paediatric short stature: The mediating role of caregiving stress.
Silva N, Bullinger M, Sommer R, et al.
Clinical psychology & psychotherapy 2018; (25(1)):e107-e118 doi:10.1002/cpp.2146.
PMID: 28960605 - 18
Growth hormone treatment in children with short stature: impact of the diagnosis on parents.
Witt S, Bloemeke J, Bullinger M, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2024; (37(4)):326-335 doi:10.1515/jpem-2023-0420.
PMID: 38421314 - 19
Quality of Life of Children and Adolescents with Short Stature: The Twofold Contribution of Physical Growth and Adaptive Height-Related Cognitive Beliefs.
Mergulhão B, Almeida JP, Moreira H, et al.
Journal of clinical psychology in medical settings 2022; (29(2)):466-475 doi:10.1007/s10880-022-09871-y.
PMID: 35511326
This page is for informational purposes only and does not constitute medical advice. Your child's pediatric endocrinologist should tailor monitoring and treatment to their growth, puberty, and overall health.